MarketPulse

Atara Biotherapeutics

14 articles
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

Atara Biotherapeutics Faces Class Action Over Alleged Securities Fraud in $ATRA Stock

Schall Law Firm recruits investors for class action against $ATRA over alleged false statements on manufacturing issues and ALLELE study deficiencies for tabelecleucel.
ATRAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Atara Biotherapeutics Faces Class Action Over Alleged Misstatements on Drug Approval Prospects

Rosen Law Firm launches class action against Atara Biotherapeutics for alleged false statements regarding manufacturing and drug approval prospects. Lead plaintiff deadline: May 22, 2026.
ATRAsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Atara Biotherapeutics Faces Class Action Over Alleged Misstatements on Drug Candidate

Class action lawsuit filed against $ATARA alleging securities fraud over false statements regarding manufacturing issues and ALLELE study deficiencies affecting tabelecleucel approval prospects.
AQSTSLNOATRAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

ATRA Stock Investors Face Critical Deadline in Securities Class Action Over FDA Setback

Securities lawsuit filed against Atara Biotherapeutics over alleged misstatements regarding tabelecleucel manufacturing and failed ALLELE study. Lead plaintiff deadline May 22, 2026.
ATRAinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

Atara Biotherapeutics Faces Securities Fraud Lawsuit Over Concealed Manufacturing, Clinical Trial Issues

Schall Law Firm launches securities fraud lawsuit against Atara Biotherapeutics for allegedly misrepresenting manufacturing capabilities and tabelecleucel trial results during May 2024-January 2026 period.
ATRAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Atara Biotherapeutics Faces Class Action Over Alleged Misstatements on Drug Approval

Class action lawsuit filed against $ATARA alleging executives misled investors about manufacturing issues and study deficiencies affecting tabelecleucel FDA approval prospects.
ATRAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

Atara Biotherapeutics Faces Securities Fraud Lawsuit Over Misleading Drug Trial Claims

Schall Law Firm launches class action against $ATRA for allegedly concealing manufacturing problems and overstating tabelecleucel prospects in ALLELE study.
ATRAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··The Gross Law Firm

ATRA Faces Securities Class Action Over FDA Drug Approval Setbacks

Shareholders sue Atara Biotherapeutics for allegedly misleading statements on manufacturing issues and failed ALLELE study data affecting tabelecleucel approval prospects.
ATRAshareholder lawsuitsecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

Atara Biotherapeutics Faces Class Action Over Alleged Securities Fraud

Schall Law Firm recruits investors for class action against Atara Biotherapeutics over alleged securities fraud involving tabelecleucel drug and ALLELE study claims, covering May 2024-January 2026 purchases.
ATRAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Securities Lawsuit Targets Atara Biotherapeutics Over Tabelecleucel Disclosure Failures

Securities lawsuit alleges Atara Biotherapeutics concealed manufacturing issues and clinical study deficiencies for tabelecleucel. Investors with $100K+ losses must act before May 22, 2026 deadline.
ATRAinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Atara Biotherapeutics Faces Securities Class Action Over FDA Study Misstatements

Securities lawsuit filed against $ATRA over alleged false statements on manufacturing issues and ALLELE study deficiencies affecting tabelecleucel approval prospects.
ATRAsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Class Action Alleges Atara Biotherapeutics Concealed Manufacturing and Trial Defects

Class action lawsuit filed against Atara Biotherapeutics for allegedly misrepresenting manufacturing issues and ALLELE study deficiencies affecting tabelecleucel approval prospects.
ATRAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Atara Biotherapeutics Faces Securities Lawsuit Over Tabelecleucel Manufacturing Claims

Rosen Law Firm urges $ATRA investors to join class action alleging false statements about manufacturing and regulatory prospects for tabelecleucel drug.
ATRAsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Atara Biotherapeutics Hit With Securities Lawsuit Over Tabelecleucel Drug Claims

Rosen Law Firm sues Atara Biotherapeutics for allegedly misrepresenting tabelecleucel drug's regulatory prospects and manufacturing capabilities to investors between May 2024 and January 2026. Lead plaintiff deadline set for May 22, 2026.
ATRAsecurities class actionmisleading statements